Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model by Xiao, Zhengwen et al.
Clinical Medicine Insights: Oncology 2011:5 315–323
doi: 10.4137/CMO.S7658
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology
OrIgInAL reSeArCh
Clinical Medicine Insights: Oncology 2011:5  315
Antitumor Efficacy of Intravesical BCG, Gemcitabine, 
Interferon-α and Interleukin-2 as Mono- or Combination-
Therapy for Bladder Cancer in an Orthotopic Tumor Model
Zhengwen Xiao, erich hanel, Allan Mak and ronald B. Moore
Departments of Surgery and Oncology, Faculty of Medicine, University of Alberta, edmonton, Alberta, Canada. 
Corresponding author email: ron.moore@albertahealthservices.ca
Abstract
Objective: To reduce adverse effects and improve efficacy of intravesical BCG for bladder cancer, alternative treatment options were 
investigated in an orthotopic rat tumor model.
Methods: Superficial bladder cancer was established in syngeneic female rat bladders by instillation of AY-27 cells. Animals were ran-
domly assigned to treatment groups including dose escalation of intravesical BCG with or without interferon-α (IFN-α) or interleukin-2 
(IL-2); or graded doses of gemcitabine alone; or BCG plus gemcitabine. Treatments were given twice weekly for 3 weeks. Rats in 
control groups received saline instillations. Treatment response was monitored by animals’ well-being, survival days, tumor growth 
inhibition, and histological examination at necropsy.
Results: Rats receiving monotherapy with intravesical BCG, gemcitabine, or IFN-α, attained significantly better survival and tumor 
reduction compared with control (P = 0.002; 0.001; 0.002, respectively, Log-rank Test). A dose-dependent treatment response was 
observed in animals with established bladder tumor receiving escalated BCG instillations. Only high-dose BCG significantly improved 
animal survival. Although high-dose BCG plus gemcitabine or IFN-α did not increase benefit over monotherapies, low-dose BCG plus 
IL-2 did show improved efficacy (P = 0.01).
Conclusion: Intravesical monotherapies with gemcitabine and IFN-α were as effective as BCG for treatment of early non-muscle-
invasive urothelial bladder cancer in this immune competent rat model. Combining these agents with high-dose BCG did not further 
increase efficacy. However, combining low-dose BCG with IL-2 enhanced BCG effectiveness.
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Introduction
Urothelial cancer of the bladder (UCB) is the fourth 
most  common  malignancy  diagnosed  in  American 
men.1  The  majority  of  these  cancers  are  non-
muscle-invasive  lesions  at  the  time  of  diagnosis. 
Non-muscle-invasive urothelial cancer has a high inci-
dence of recurrence (up to 75%) which requires close 
monitoring.2,3 The main goal of intravesical therapy 
is to prevent tumor recurrence and progression fol-
lowing initial transurethral resection of bladder tumor 
(TURBT).  Intravesical  bacillus  Calmette-Guérin 
(BCG) is so far the most effective and common form 
of  adjuvant  therapy  for  high  risk  bladder  cancer.4 
Compared  with  controls,  BCG  immunotherapy  has 
superior  advantage  in  preventing  tumor  recurrence 
than intravesical chemotherapy.5,6 In contrast to intra-
vesical chemotherapy, BCG has also been shown to 
reduce the risk of tumor progression.3 Despite its suc-
cess, significant proportions (30%–40%) of patients 
do not respond to BCG therapy and 30% to 50% of 
initial  responders  have  relapse  within  the  first  five 
years.7 Furthermore, side-effects are common, which 
may be related to BCG dose, especially in highly sen-
sitive patients.8 BCG elicits a non-specific immune 
response  within  the  bladder  wall.  This  response  is 
T-lymphocyte  dependent  and  is  mediated  by  both 
T-helper 1 (Th1) and T-helper 2 (Th2) cytokines.9,10 
CD4+ Th1 cytokines [interleukin 2 (IL-2) and interfer-
ons (IFNs)] lead to activation of lymphokine activated 
killer  cells,  macrophages,  NK  cells,  and  apoptotic 
pathways.11,12 The apoptotic pathways are thought to be 
related to the tumor necrosis factor-related apoptosis-
inducing  ligand  (TRAIL).13,14  TRAIL  can  trigger 
both the extrinsic and intrinsic apoptotic pathways.15 
Preliminary clinical studies of combination therapy 
with IFN-α plus low dose BCG demonstrate 42% to 
53% tumor-free at 2 years in BCG refractory patients, 
for which effective alternative therapy remains very 
limited.16,17 Also, combining low-dose BCG plus CD4+ 
cytokines  has  been  suggested  to  reduce  BCG  side 
effects.18 In addition, IL-2 has been shown in some 
clinical  studies  to  have  a  direct  antitumor  effect.19 
Furthermore,  there  is  strong  experimental  evidence 
for maximally activating the apoptotic pathways with 
combination treatment of gemcitabine and TRAIL in 
urothelial cancer cells.20
Gemcitabine  (2′-deoxy-2′,  2′-difluorocytidine, 
Gemzar®), is a nucleoside analogue with a molecular 
weight of 299.66 that is metabolized   intracellularly 
by nucleoside kinases to the active diphosphate and 
triphosphate nucleosides. It primarily kills cells under-
going DNA synthesis (S-phase). Studies have shown 
it can also promote tumor cell apoptosis,21 which may 
enhance the antitumor effect of BCG if used together 
as an intravesical agent.22
The ultimate goal of cancer therapy is to achieve 
maximal antitumor efficacy and minimal toxicity. To 
reach this goal, we investigated the antitumor effi-
cacy of some alternative modalities including gem-
citabine, IFN-α, IL-2, alone or in combination with 
BCG,  which  was  compared  to  BCG  monotherapy 
and saline control. Ideally new therapeutic strategies 
should be tested rigorously in relevant animal mod-
els. Thus, a previously well characterized orthotopic, 
immune competent rat bladder cancer model23–25 was 
used in this study.
Materials and Methods
Tumor cells, BCg, and gemcitabine
The AY-27  cell  line  was  originally  induced  in  the 
bladders of Fischer F344 rats by using the FANFT 
carcinogen. The cells were cultured as monolayers 
in RPMI-1640 medium (Gibco-BRL) supplemented 
with 10% heat inactivated fetal bovine serum in 37 °C 
humidified 5% CO2. These cells were passaged using 
standard trypsinization protocols and were previously 
characterized to confirm their urothelial cell origin by 
immunohistochemical analysis.23
Connaught strain BCG was initially provided by 
Aventis  Pharmaceuticals  (formerly  Pasteur-Merieux 
Connaught, Montreal, QC, Canada). It was assayed 
for colony forming unit (cFU) quality by the manufac-
turer and our treatment aliquots were based on these 
functional calculations. This strain of BCG was used in 
the first part of the study. Our hospitals later switched 
over to use Tice strain BCG (OncoTICE®, Organon 
Canada Ltd., Toronto, ON) in patients. Accordingly, 
we used Tice strain BCG in the second part of the ani-
mal study. The medium BCG dose (2 × 106 cFU/ml) 
used for the animal studies was based on the clinically 
used dose (1–8 × 106 cFU/ml). All lyophilized BCG 
aliquots were protected from light and stored at 4 °C. 
BCG was used in aliquots and never stored after being 
reconstituted in sterile saline (0.9% NaCl).
The lyophilized powder of gemcitabine (Eli Lilly 
Canada Inc., Toronto, ON) was first reconstituted with Intravesical BCg, gemcitabine, IFn-α and IL-2
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saline, aliquoted and stored at −20 °C. These aliquots 
were further diluted to the desired concentrations with 
Dulbecco’s phosphate buffered saline (PBS, pH 7.4) 
before each experiment.
Animals
All animal procedures were carried out in accordance 
with  guidelines  regulated  by  the  Canadian  Coun-
cil on Animal Care and approved by the University 
of  Alberta  Institutional  Animal  Care  Committee. 
Female Fischer F344 rats weighing ∼150 gm were 
used for tumor implantation and randomly assigned 
to  experimental  groups  (Tables  1  and  2). Animals 
were initially purchased from Charles River Labora-
tories (Quebec, Canada) and bred locally in the Cross 
Cancer Institute vivarium. Sterile technique was used 
for  all  procedures  including  catheterization  of  the   
animals.
Tumor cell implantation and intravesical 
therapy
Tumor cell implantation procedures were previously 
reported  by  us.23,26  Briefly,  animals  were  anesthe-
tized  with  inhalation  of  2%  Isoflurane  in  oxygen. 
The  bladder  was  catheterized  with  an  18  gauge 
angiocatheter  (BD  Insyte™,  Utah,  USA)  and  the 
mucosa   preconditioned with 0.1 M HCl, neutralized 
with  0.1  M  KOH,  and  then  flushed  with  sterile 
PBS  (pH  7.4)  3  times.  Single  cell  suspensions  of 
AY-27 cells (3 × 106) in 500 µl of serum-free medium 
were then instilled via the catheter and left indwell-
ing for 1 h. The rats’ position was changed from side 
to side to facilitate full bladder wall exposure. The 
catheter was removed after 1 h and the rats were 
allowed  to  void  spontaneously. The  well-being  of 
the rats was monitored daily. With this instillation 
procedure, nearly 100% tumor engraftment has been 
achieved in syngeneic Fisher F344 rats if 2 × 106 or 
more tumor cells are inoculated.23–25
Based  on  our  prior  study  using  reovirus  in  the 
same tumor model,26 treatments with dose escalation 
of intravesical BCG (Connaught strain) or BCG plus 
IL-2 (Invitrogen) commenced on day 10 after tumor 
cell inoculation (Table 1). BCG doses ranged from 
5 × 105 cFU/ml (low-dose) to 5 × 107 cFU/ml (high-
dose). Low-dose BCG plus IL-2 (5 × 105 Units) was 
used  for  combination  treatment.  Control  animals 
received normal saline instillations. Treatments were 
administered twice weekly for 3 weeks. Instilled vol-
ume was 0.5 ml per treatment. To ensure accurate drug 
exposure a purse-string suture was placed in the skin 
around the urethral meatus to keep the solutions in 
the bladder while the animals were under anesthesia. 
The suture was removed 2 h later. After treatment the 
animals were monitored daily. Urine was collected 
for cytology at day 0, 10 and 60. In cases where urine 
could not be collected directly (ie, empty bladder) 
0.5 ml of normal saline was flushed into the bladder 
and collected for cytology.
A 9.4T rodent magnetic resonance imaging (MRI, 
Magnex Scientific, Oxford, UK) was used to monitor 
bladder tumor growth. Although the 9.4T MRI had 
better resolution (0.5 mm) than the 1.5T clinical MRI 
we used previously,23 it was still difficult to visualize 
tiny or flat tumors (Fig. 1). The MRI did detect papil-
lary tumors and some were fairly large after 10 days 
post-inoculation (Fig. 1), suggesting that intravesical 
BCG should possibly be started earlier. Therefore in 
the second part of the study, treatments with gemcit-
abine commenced at day 6 post-implantation (Table 2). 
Graded doses of gemcitabine ranging from 0.5 mg/ml 
to 20 mg/ml, or BCG (2 × 107 cFU/ml), or recombi-
nant rat IFN-α (Invitrogen, 18000 Units) were given 
intravesically twice weekly for 3 weeks. Combination 
Table 1. Fisher rats receiving intravesical treatments starting 10 days after inoculation of 3-million AY-27 rat UCC cells.
Treatment  
groups
BCG†  
concentration
Treatment  
schedule
No. rats No. LTS§ No. (LTS)  
tumor-free
P value  
vs. saline
Low BCg 5 × 105 cFU/ml Twice/wk, 3 wks 10 2 0 0.115
Medium 5 × 106 cFU/ml Twice/wk, 3 wks 10 4 3 0.05
high BCg 5 × 107 cFU/ml Twice/wk, 3 wks 10 5 4 0.03
IL-2¶ + low BCg 5 × 105 cFU/ml Twice/wk, 3 wks 10 5 3 0.01
0.9% naCl not applicable Twice/wk, 3 wks 10 1 1 not applicable
Notes: †Connaught strain of BCg was used; instilled volume was 0.5 ml per treatment. ¶recombinant IL-2; 5 × 105 units per treatment. §LTS means long-
term survival, which is that rat survives greater than 90 days post implantation.Xiao et al
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therapies of BCG plus gemcitabine (0.5 mg/ml) or 
IFN-α were administered. Once again, animals in a 
control group received saline instillations.   Treatment 
procedures were identical to the first part of the study. 
However, urine cytology and MRI were abandoned 
due to their limitations in tumor detection.
Follow-up endpoint
Once the animals completed the treatment regimes, 
they were observed for more than 90 days for signs 
and symptoms of bladder cancer progression (body 
weight  loss,  hematuria,  and  urinary  retention). 
Animals  were  then  euthanized  using  pentobarbital 
  (Euthanyl®,  Bimeda-MTC  Animal  Health  Inc.) 
overdose  and  subjected  to  necropsy.  The  bladders 
and kidneys were excised for gross and histological 
examination  (standard  formalin  fixation,  section-
ing, and hematoxylin and eosin staining). Sections 
were  microscopically  reviewed  by  a  pathologist. 
Tumor stage and grade, and extent of inflammatory 
cell  infiltration  were  recorded.  Other  organs  that 
appeared  grossly  abnormal  were  also  excised  and 
studied microscopically. If animals became severely 
distressed they were euthanized earlier and necropsy 
 performed.
Statistic analysis
Survival  curves  from  different  groups  of  animals 
were plotted by the Kaplan-Meier method. Log-rank 
(Mantel-Cox) test (GraphPad Prism®, version 5.01, 
San Diego, USA) was used to compare survival time 
distributions. Individual groups were compared rel-
ative to control groups to calculate P values and a 
P , 0.05 was considered significant.
Results
Table 1 and Figure 2 summarize the data from tumor-
bearing rats treated by graded doses of BCG alone 
or low-dose BCG plus IL-2 starting at 10 days post 
tumor  cell  inoculation.  Animals  surviving  greater 
than 90 days post-implantation were considered long-
term survivals (LTS). A dose-dependent tumor cure 
(tumor-free animals in LTS) and survival benefit were 
observed  from  intravesical  BCG  monotherapies. 
High-dose BCG attained significant survival benefit 
compared to control (P = 0.03), while low-dose BCG 
A
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Figure 1. Orthotopic rat bladder tumors post-inoculation of 3 × 106 AY-27 
UCC cells. (A), a gross photograph of a rat bladder, which is sagittally 
cut open from the anterior wall at 14 days post-implant, shows a solid 
tumor on the left side of the bladder cavity (open arrow). There are also 
multiple tiny ‘satellite’ tumors (small arrows) surrounding the solid tumor. 
(B), a transverse view of an Mr image of the rat scanned with the 9.4T 
rodent MrI demonstrates a solid bladder tumor (open arrow) protruding 
to the bladder lumen (BL) from the bladder wall. With MRI, it is difficult to 
detect satellite tiny tumors shown in (A) and flat lesions. MR imaging was 
performed using T2-weighted scans (Tr = 3000 ms, Te = 35 ms) with 
slice thickness of 1.0 mm. A total of 20 consecutive slices were scanned 
per bladder, which was filled with 0.5 ml of saline. (c), a bladder sec-
tion (H&E staining) 7 days post-inoculation shows early stage (flat) UCB. 
Scale bar denotes 1 cm in 1B; or 200 µm in 1C.
Table 2. Fisher rats receiving intravesical treatments starting 6 days after inoculation of 3-million AY-27 rat UCC cells.
Treatment  
groups
Drug  
concentration
Treatment  
schedule
No. rats No. LTS No. (LTS)  
tumor-free
P value  
vs. saline
Control 0.9% naCl Twice/wk, 3 wks 12 1 1 not applicable
gemzar A .10 mg/ml Not finished 6 0
gemzar B 2 mg/ml Twice/wk, 3 wks 10 7 5 0.005
gemzar C 1 mg/ml Twice/wk, 3 wks 10 9 4 0.001
gemzar D 0.5 mg/ml Twice/wk, 3 wks 10 7 6 0.001
BCg (Tice®) 2 × 107 cFU/ml Twice/wk, 3 wks 12 8 7 0.002
gemzar/BCg 0.5 mg/ml  
2 × 107 cFU/ml
Twice/wk, 3 wks 9 4 5 0.046
rIFn 18 000 IU Twice/wk, 3 wks 12 8 7 0.002
rIFn/BCg 18 000 IU  
2 × 107 cFU/ml
Twice/wk, 3 wks 11 6 6 0.005
Note: Instilled volume was 0.5 ml per treatment.Intravesical BCg, gemcitabine, IFn-α and IL-2
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did not (P = 0.115). Interestingly, when combining 
low-dose BCG with IL-2 similar efficacy to high-dose 
BCG was obtained (P = 0.01). Surprisingly, the ben-
efit from medium-dose BCG (equivalent to dose used 
clinically) over saline instillations just reached sig-
nificance (P = 0.05). The tumor burden at the time of 
treatment could have been a potential cause of failure, 
since MRI and histological examination at 10 days 
post tumor cell inoculation revealed some relatively 
‘large’ papillary tumors with early invasion (Fig. 1). 
Clinically, intravesical BCG has been used mainly for 
treatment of carcinoma in situ or for minimal residual 
tumor following surgery to eliminate recurrence and 
progression.
Histological slides of bladder tissue did not detect 
marked difference of inflammatory cell infiltration 
between BCG and BCG plus IL-2 treated groups, 
suggesting that IL-2 may act directly on tumor cells. 
Urine cytology detected less than 50% of bladder 
tumors  when  compared  with  histological  exami-
nation at necrospy. During and after BCG therapy, 
animals showed various degrees of distress (ocular 
porphyrin staining, hematuria and poor grooming). 
The main cause for animals to be terminated earlier 
was  urinary  retention  (lower  abdomen  distention) 
resulting from bladder tumor and/or dystrophic stone 
obstruction  of  bladder  outlet.  Pyelonephritis  was 
observed in 15% of animals, which might be related 
to tumor obstruction or reflux which is   common in 
this model.
In the second part of the study, we investigated 
the efficacy of alternative agents in this tumor model 
using BCG as a standard treatment. In an attempt to 
treat  animals  with  less  tumor  burden,  intravesical 
treatments  in  this  part  of  the  study  commenced  at 
6 days post-inoculation when mostly flat UCB was 
present (Fig. 1C). Data from the second part of the 
study are shown in Table 2 and Figure 3. Consistent 
to the first part, animals treated with BCG (Tice strain, 
2 × 107 cFU/ml) instillations showed a significant sur-
vival advantage (66.7% LTS, P = 0.002) and tumor cure 
(tumor-free in LTS) compared with saline controls. 
Animals receiving gemcitabine instillations (0.5, 1, 
and 2 mg/ml) also attained 70–90% long-term survival, 
with 40–60% tumor cure, which were significantly 
different  from  animals  receiving  saline  instillations 
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Figure 2. Kaplan Meier survival curves of rats bearing AY-27 bladder cancer and receiving BCg instillations commenced at day 10 post-implantation.   
A BCG dose-dependent survival is shown. Compared with saline control, high-dose BCG improved survival significantly (P = 0.03), while low-dose BCg 
appeared to be less effective (P = 0.115). IL-2 plus low-dose BCG enhanced efficacy of BCG monotherapy (P = 0.01).Xiao et al
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(P = 0.001, = 0.001, = 0.005, respectively). Since no 
dose-response was observed between the lower-dose 
gemcitabine groups, they were pooled into one group 
for survival analysis to generate a concise and more 
readable figure (Fig. 3). However, it should be noted 
that animals treated with higher doses of gemcitabine 
(10 and 20 mg/ml) died from toxicity after 2 instilla-
tions; as such, they were excluded from analysis as 
they did not finish the treatment schedule. Necropsy of 
these high-dose treated animals revealed hemorrhagic 
cystitis and gastrointestinal bleeding which appeared 
to be the etiology of death.
To test if gemcitabine could increase efficacy of 
BCG  by  targeting  both  the  intrinsic  and  extrinsic 
apoptotic pathways, one group of animals received 
BCG (2 × 107 cFU/ml) plus gemcitabine (0.5 mg/ml) 
instillations. Unfortunately, this combination did not 
further increase effectiveness, but it slightly reduced 
the animals’ tolerance to treatment (44% LTS). Sur-
prisingly, rats receiving IFN-α alone instillations dis-
played similar effectiveness to BCG alone treatment. 
Interestingly, combining BCG (2 × 107 cFU/ml) with 
IFN-α did not enhance effectiveness over high-dose 
BCG monotherapy.
Discussion
Transurethral resection is the initial treatment for 
patients with non-muscle invasive UCB.  Unfortu-
nately, these tumors recur in 40% to 80% of patients 
following TURBT.27 To  prevent  tumor  recurrence 
and progression, intravesical instillation of BCG is 
the most commonly used adjuvant therapy. To date, 
there are limited proven effective alternative intra-
vesical therapies for patients with BCG-refractory 
bladder  cancers.  Increasing  the  dose  of  BCG  or 
enhancing the treatment schedules was suggested, 
but  was  associated  with  higher  toxicities.8,18  The 
doses of BCG used clinically are largely empirical 
and there is limited data in literature to show that 
BCG  efficacy  is  dose-dependent.  Studies  in  ani-
mals and preliminary clinical trials have shown that 
gemcitabine and IFN may be promising intravesical 
agents which could be used as monotherapy or in 
combination therapy with BCG.12,17,18,21,28 However, 
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Figure 3. Kaplan Meier survival curves of rats bearing AY-27 bladder cancer and receiving instillations of gemcitabine, Tice strain BCg, IFn-α, or combina-
tion of these agents commenced at day 6 post-implantation. For clarity purpose, animals receiving lower doses of gemcitabine (0.5, 1.0, 2.0 mg/ml) were 
pooled together for survival analysis due to their similar survival data (see Table 2). Animals treated with gemcitabine (gemzar), BCg, or IFn-α (rIFn) 
all attain significant survival benefits, compared with controls treated with saline (P = 0.0001). Combining BCg with gemcitabine or IFn has not further 
increased antitumor response.Intravesical BCg, gemcitabine, IFn-α and IL-2
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studies  to  date  have  been  performed  in  various 
different clinical settings. To the best of our knowl-
edge, there has been no side-by-side comparative 
studies performed using all these agents in a single 
preclinical animal model. In the present study, we 
used a well characterized syngeneic rat orthotopic 
bladder tumor model to examine gemcitabine as an 
alternative regional chemotherapeutic agent (which 
could be clinically administered earlier post-TURBT 
than  the  infectious  BCG)  and  compared  it  with 
BCG. We also explored combination therapies of 
BCG plus gemcitabine, or T lymphocyte cytokines. 
The rationale for combining gemcitabine with BCG 
was to maximize apoptosis in UCC, as demonstrated 
in our previous in-vitro studies, where gemcitabine 
reduced  Bcl-2  expression  and  enhanced  TRAIL 
mediated apoptosis.20
We first performed a BCG dose escalation study 
because such a study is difficult to do in patients.   
A  dose–dependent  antitumor  and  survival  effect 
was  shown  in  animals  receiving  BCG  instilla-
tions started 10 days post-inoculation of UCC cells 
(Table 1, Fig. 2). High-dose BCG treatments sig-
nificantly improved survival benefit and tumor cure 
versus  saline  control.  Low-dose  BCG  alone  did 
not  demonstrate  a  significant  benefit  over  saline. 
The clinically equivalent medium-dose BCG treat-
ment  demonstrated  a  marginally  significant  anti-
tumor and survival benefit (P = 0.05, Mantel-Cox 
test) over saline. Combination therapy of low-dose 
BCG with IL-2 significantly enhanced BCG’s anti-
tumor efficacy, which concurs with clinical results 
of combining low-dose BCG with INF-α.16 Urinary 
IL-2 seems a positive predictor of response to BCG 
therapy.9,10 Histological examination has not found 
noticeable difference of inflammatory cell infiltra-
tion between BCG and BCG plus IL-2 treated blad-
der tissues, which may suggest IL-2 (effector) has 
direct antitumor effect and enhances BCG’s indirect 
(activator) activity.9
The reason for the lack of efficacy of low-dose 
BCG alone is not clear. We thought a heavier tumor 
burden at 10 days (rather than 6 days, Fig. 1) post-
  inoculation may be one of the obstacles for BCG 
therapy. This was based on the criteria established 
by  Zbar,  that  successful  BCG  therapy  requires 
close contact between BCG and tumor cells, a lim-
ited tumor burden, a host capable of mounting an 
immunological reaction to mycobacterial antigens 
and adequate numbers of viable BCG organisms.4 
  Clinically, BCG is used to treat bladder flat lesions 
(CIS) or residual tumor cells.
We then examined the efficacy of gemcitabine 
and IFN-α, as well as in combination with high-
dose BCG. Treatments were started earlier (6 days 
post tumor inoculation). The rationale of this was 
two-fold: 1, gemcitabine and INF-α are not infec-
tious agents and can be used earlier than BCG in 
the clinic, and 2,the tumors tended to have early 
invasion  (pT1  disease)  beyond  6  days.  Gemcit-
abine (low dose; 0.5–2 mg/ml), IFN-α, and BCG 
all demonstrated significantly superior antitumor 
responses  (tumor-free  long-term  survival)  when 
compared with saline controls (Table 2 and Fig. 3). 
Animals tolerated the treatments well. These data 
show that gemcitabine and INF-α may be prom-
ising  alternative  agents  to  BCG,  especially  in 
BCG-refractory patients. Also, we believe this is 
the first time to examine the two commonly used 
BCG strains in one study. Although the timing of 
BCG initiation was slightly different, both strains 
of high-dose BCG showed highly effective anti-
tumor activity. Animals treated with high concen-
trations of gemcitabine (10–20 mg/ml) could not 
tolerate beyond 2 instillations and died from drug 
related toxicities. These toxicities may be attribut-
able to an acidic chemical effect on the thin blad-
der wall at high drug concentration (pH of ∼3.0) 
and systemic absorption of the drug. Absorption 
of gemcitabine (molecular weight, 299.66) may be 
facilitated by vesicoureteral reflux to kidneys in 
our rat model.29 Systemic absorption in dogs after 
instillation has also been reported.30   Fortunately, 
absorption  of  gemcitabine  following  instillation 
in  humans  appears  to  be  limited,28,31  which  has 
allowed for dose escalation to facilitate a concen-
tration gradient driven tissue penetration in human 
bladders. Contrary to our hypothesis, combining 
high-dose  BCG  with  gemcitabine  or  IFN-α  did 
not further increase their antitumor efficacy over 
monotherapy of either agent. It seems that a maxi-
mal  antitumor  activity  of  the  monotherapy  has 
been reached and there is limited room for further 
improvement from combining them in our model 
system. If this is the case, then rational combina-
tion therapy is more suitable for low-dose BCG Xiao et al
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plus gemcitabine or Th1 cytokines in the treatment 
of early stage bladder cancer.
Conclusions
Based  on  the  study  in  an  orthotopic  rat  bladder 
tumor model, the antitumor efficacy of BCG is dose-
  dependent. IL-2 enhanced low-dose BCG’s efficacy 
to the level of high-dose BCG treatment. Gemcitabine 
and IFN-α monotherapy showed similar efficacy to 
  high-dose BCG and are promising intravesical agents 
for treatment of early stage UCB. These alternative 
and  combinatory  strategies  warrant  further  explo-
ration  in  patients  with  non-muscle  invasive  UCB, 
especially in those with BCG-refractory diseases.
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